Loading...

Abeona Therapeutics

DB:PCJP
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PCJP
DB
$396M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops cell and gene therapies for life-threatening rare genetic diseases. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
PCJP Share Price and Events
7 Day Returns
2.2%
DB:PCJP
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-50.5%
DB:PCJP
-7.4%
DE Biotechs
-5.6%
DE Market
PCJP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Abeona Therapeutics (PCJP) 2.2% 11.2% 24% -50.5% 205.8% -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • PCJP underperformed the Biotechs industry which returned -7.4% over the past year.
  • PCJP underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
PCJP
Industry
5yr Volatility vs Market

Value

 Is Abeona Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Abeona Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Abeona Therapeutics.

DB:PCJP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:PCJP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 21%) (0%))
1.303
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.303 * 5.96%)
8%

Discounted Cash Flow Calculation for DB:PCJP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Abeona Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:PCJP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8%)
2019 -64.56 Analyst x1 -59.78
2020 -86.94 Analyst x1 -74.54
2021 -95.26 Analyst x1 -75.62
2022 -38.28 Analyst x1 -28.14
2023 26.35 Analyst x1 17.94
2024 38.24 Est @ 45.12% 24.10
2025 50.35 Est @ 31.65% 29.38
2026 61.54 Est @ 22.22% 33.26
2027 71.15 Est @ 15.62% 35.60
2028 78.98 Est @ 11.01% 36.60
Present value of next 10 years cash flows $-61.20
DB:PCJP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $78.98 × (1 + 0.23%) ÷ (8% – 0.23%)
$1,019.04
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,019.04 ÷ (1 + 8%)10
$472.17
DB:PCJP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-61.20 + $472.17
$410.96
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $410.96 / 48.09
$8.55
DB:PCJP Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:PCJP represents 0.87283x of NasdaqCM:ABEO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87283x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 8.55 x 0.87283
€7.46
Value per share (EUR) From above. €7.46
Current discount Discount to share price of €7.23
= -1 x (€7.23 - €7.46) / €7.46
3.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Abeona Therapeutics is available for.
Intrinsic value
3%
Share price is €7.23 vs Future cash flow value of €7.46
Current Discount Checks
For Abeona Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Abeona Therapeutics's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Abeona Therapeutics's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Abeona Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Abeona Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PCJP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.19
NasdaqCM:ABEO Share Price ** NasdaqCM (2019-04-24) in USD $8.28
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Abeona Therapeutics.

DB:PCJP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ABEO Share Price ÷ EPS (both in USD)

= 8.28 ÷ -1.19

-6.94x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Abeona Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Abeona Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Abeona Therapeutics's expected growth come at a high price?
Raw Data
DB:PCJP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.94x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
52.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Abeona Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Abeona Therapeutics's assets?
Raw Data
DB:PCJP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.80
NasdaqCM:ABEO Share Price * NasdaqCM (2019-04-24) in USD $8.28
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:PCJP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ABEO Share Price ÷ Book Value per Share (both in USD)

= 8.28 ÷ 2.80

2.96x

* Primary Listing of Abeona Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Abeona Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Abeona Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Abeona Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Abeona Therapeutics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
52.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Abeona Therapeutics expected to grow at an attractive rate?
  • Abeona Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Abeona Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Abeona Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:PCJP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:PCJP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 52.7%
DB:PCJP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 64.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PCJP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PCJP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 562 460 3
2022-12-31 180 253 2
2021-12-31 19 -57 4
2020-12-31 1 -74 4
2019-12-31 3 -67 6
DB:PCJP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 3 -39 -57
2018-09-30 5 -27 -45
2018-06-30 4 -25 -34
2018-03-31 3 -21 -31
2017-12-31 1 -23 -27
2017-09-30 1 -21 -26
2017-06-30 1 -18 -23
2017-03-31 1 -16 -22
2016-12-31 1 -13 -22
2016-09-30 1 -12 -17
2016-06-30 1 -11 -21
2016-03-31 1 -10 -18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Abeona Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Abeona Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PCJP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Abeona Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PCJP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 7.83 11.21 4.45 2.00
2022-12-31 4.56 8.08 1.04 2.00
2021-12-31 0.04 1.93 -1.16 3.00
2020-12-31 -1.36 -1.07 -1.74 5.00
2019-12-31 -1.35 -1.08 -1.54 6.00
DB:PCJP Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.19
2018-09-30 -0.96
2018-06-30 -0.75
2018-03-31 -0.70
2017-12-31 -0.66
2017-09-30 -0.65
2017-06-30 -0.61
2017-03-31 -0.60
2016-12-31 -0.64
2016-09-30 -0.52
2016-06-30 -0.63
2016-03-31 -0.59

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Abeona Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Abeona Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Abeona Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Abeona Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Abeona Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Abeona Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Abeona Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Abeona Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Abeona Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Abeona Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PCJP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 3.00 -56.67 20.11
2018-09-30 5.34 -45.03 15.59 16.99
2018-06-30 3.85 -33.96 12.78 16.99
2018-03-31 3.25 -30.54 10.80 16.99
2017-12-31 0.84 -27.32 10.94
2017-09-30 0.88 -25.87 10.63 3.04
2017-06-30 0.84 -23.15 10.86 5.78
2017-03-31 0.84 -21.58 11.95 8.80
2016-12-31 0.89 -21.87 13.29
2016-09-30 0.85 -17.21 14.73 9.69
2016-06-30 0.95 -20.66 17.06 8.53
2016-03-31 1.02 -18.07 17.00 6.12
2015-12-31 1.04 -14.53 14.32 4.72
2015-09-30 1.06 -24.81 10.73 2.68
2015-06-30 1.01 -20.95 6.81 1.17
2015-03-31 0.98 -30.07 4.01 0.64
2014-12-31 0.93 -29.65 3.71 0.33
2014-09-30 0.85 -18.80 3.77 0.43
2014-06-30 0.81 -17.49 3.62 0.59
2014-03-31 1.03 -3.39 4.89 0.71
2013-12-31 2.04 1.55 4.83 0.88
2013-09-30 2.89 22.47 5.65 1.05
2013-06-30 3.57 8.06 6.43 1.13
2013-03-31 3.79 -3.85 5.70 1.58
2012-12-31 4.40 -12.53 6.02 2.01
2012-09-30 3.90 -31.85 5.82 2.47
2012-06-30 4.07 -16.63 6.20 3.07

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Abeona Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Abeona Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Abeona Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Abeona Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Abeona Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Abeona Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Abeona Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Abeona Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Abeona Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Abeona Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Abeona Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Abeona Therapeutics Company Filings, last reported 3 months ago.

DB:PCJP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 134.05 0.00 84.97
2018-09-30 150.25 0.00 112.22
2018-06-30 160.91 0.00 119.84
2018-03-31 169.20 0.00 132.00
2017-12-31 170.10 0.00 137.75
2017-09-30 89.88 0.00 56.52
2017-06-30 89.08 0.00 58.30
2017-03-31 95.71 0.00 63.21
2016-12-31 99.10 0.00 69.14
2016-09-30 63.49 0.00 31.19
2016-06-30 61.48 0.00 34.30
2016-03-31 65.66 0.00 37.40
2015-12-31 67.72 0.00 40.14
2015-09-30 73.07 0.00 43.28
2015-06-30 59.95 0.00 30.41
2015-03-31 3.16 0.00 7.95
2014-12-31 4.82 0.40 11.52
2014-09-30 -17.36 0.25 0.17
2014-06-30 -16.10 0.00 0.06
2014-03-31 -14.89 0.00 0.30
2013-12-31 -13.59 0.00 0.42
2013-09-30 -12.44 0.00 0.90
2013-06-30 -11.20 0.00 1.80
2013-03-31 -9.19 0.00 0.05
2012-12-31 -7.88 0.00 0.40
2012-09-30 -16.09 2.75 0.11
2012-06-30 -14.77 2.75 0.59
  • Abeona Therapeutics has no debt.
  • Abeona Therapeutics had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Abeona Therapeutics has sufficient cash runway for 1.4 years based on current free cash flow.
  • Abeona Therapeutics has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 55.1% each year.
X
Financial health checks
We assess Abeona Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Abeona Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Abeona Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Abeona Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Abeona Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Abeona Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Abeona Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PCJP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PCJP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Abeona Therapeutics has not reported any payouts.
  • Unable to verify if Abeona Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Abeona Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Abeona Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Abeona Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Abeona Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Abeona Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Abeona Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Abeona Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
João Siffert
AGE 55
TENURE AS CEO 0.4 years
CEO Bio

Dr. João Siffert, MD, has been Chief Executive Officer of Abeona Therapeutics Inc., since February 11, 2019. He is Head of Research and Development and Chief Medical Officer of Abeona Therapeutics Inc. since October 2018 and serves as Director. He was the Interim Chief Executive Officer of Abeona Therapeutics Inc., since November 26, 2018 until February 11, 2019. Dr. Siffert serves as Member of Scientific Advisory Board at Integra Holdings. Dr. Siffert serves as Chief Medical Officer and Executive Vice President of Research & Development at Avanir Pharmaceuticals, Inc. Dr. Siffert has over 20 years of executive-level pharmaceutical industry and clinical experience. He served as Senior Vice President of Research & Development and Chief Scientific Officer at Avanir Pharmaceuticals, Inc. since August 2011 and December 2012. Dr. Siffert served as Vice President and Chief Medical Officer of Ceregene, Inc., since October 2, 2007 where he focused on the development of neurotrophic gene therapies for Alzheimer's and Parkinson's disease. He served as Vice President, Clinical Research and Development at Avera Pharmaceuticals since June 2005 and also served its Chief Medical Officer. He was previously employed at Pfizer as a medical director since 2002, where he initially worked in the area of migraine and ultimately headed the worldwide medical team for Lyrica (pregabalin) and Neurontin in the areas of epilepsy and pain. He served as a Director of AveXis, Inc. from April 13, 2017 to May 15, 2018. He served as a Director of Alcobra Ltd. since July 13, 2015. Dr. Siffert's contributions were instrumental for the Phase IIIb and IV clinical program as well as the global product launch. Prior to joining Pfizer, Dr. Siffert had a distinguished academic career that included positions at Beth Israel Medical Center, where he served as director of their Adult Neuro-oncology program and Albert Einstein College of Medicine, where he was a faculty member in the department of neurology. He received his M.D. degree from the University of Sao Paulo School of Medicine, completed residencies in pediatrics at New York University School of Medicine and in neurology at Harvard Medical School and held a clinical fellowship in Neuro-oncology at New York University School of Medicine. He also holds an MBA degree from Columbia University Business School in New York.

CEO Compensation
  • Insufficient data for João to compare compensation growth.
  • Insufficient data for João to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Abeona Therapeutics management team in years:

0.5
Average Tenure
52
Average Age
  • The average tenure for the Abeona Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Steve Rouhandeh

TITLE
Executive Chairman
COMPENSATION
$2M
AGE
61

Tim Miller

TITLE
President & Chief Scientific Officer
COMPENSATION
$2M
AGE
46
TENURE
3.9 yrs

João Siffert

TITLE
CEO, Head of Research & Development
AGE
55
TENURE
0.4 yrs

Christine Berni-Silverstein

TITLE
Chief Financial Officer
TENURE
0.3 yrs

Edward Carr

TITLE
Chief Accounting Officer
AGE
49
TENURE
0.4 yrs

Sofia Warner

TITLE
Director of Investor Relations

Neena Patil

TITLE
Senior VP
TENURE
0.5 yrs

Scott Santiamo

TITLE
Director of Corporate Communications

Kristina Maximenko

TITLE
Global Head of Human Resources
TENURE
0.8 yrs

Kaye Spratt

TITLE
Senior Vice President of Regulatory Affairs
Board of Directors Tenure

Average tenure and age of the Abeona Therapeutics board of directors in years:

3
Average Tenure
55
Average Age
  • The average tenure for the Abeona Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

João Siffert

TITLE
CEO, Head of Research & Development
AGE
55

Mark Alvino

TITLE
Independent Director
COMPENSATION
$420K
AGE
50
TENURE
13.1 yrs

Steve Rouhandeh

TITLE
Executive Chairman
COMPENSATION
$2M
AGE
61
TENURE
4.3 yrs

Steve Howell

TITLE
Independent Director
COMPENSATION
$420K
AGE
73
TENURE
23.3 yrs

Todd Wider

TITLE
Independent Director
COMPENSATION
$904K
AGE
53
TENURE
3.9 yrs

Maria Escolar

TITLE
Member of Scientific Advisory Board

Kevin Flanigan

TITLE
Member of Scientific Advisory Board
TENURE
2 yrs

Douglas McCarty

TITLE
Member of Scientific Advisory Board
TENURE
2 yrs

Steven Gray

TITLE
Member of Scientific Advisory Board
TENURE
2 yrs

Erika Augustine

TITLE
Member of Scientific Advisory Board
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Abeona Therapeutics insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Apr 19 Buy Richard van Duyne Individual 08. Apr 19 08. Apr 19 6,000 €6.85 €41,084
12. Apr 19 Buy Stefano Buono Individual 10. Apr 19 11. Apr 19 70,000 €7.02 €484,742
10. Apr 19 Buy Stephen Howell Individual 08. Apr 19 08. Apr 19 4,000 €6.90 €27,602
X
Management checks
We assess Abeona Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Abeona Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops cell and gene therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101 an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of retinal diseases. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. Abeona Therapeutics Inc. has a license agreement with REGENXBIO Inc. for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 disease, and CLN3 disease. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is based in New York, New York.

Details
Name: Abeona Therapeutics Inc.
PCJP
Exchange: DB
Founded: 1974
$354,080,560
48,092,828
Website: http://www.abeonatherapeutics.com
Address: Abeona Therapeutics Inc.
1330 Avenue of the Americas,
33rd Floor,
New York,
New York, 10019,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ABEO Common Stock Nasdaq Capital Market US USD 26. Jan 1996
DB PCJP Common Stock Deutsche Boerse AG DE EUR 26. Jan 1996
LSE 0H7R Common Stock London Stock Exchange GB USD 26. Jan 1996
Number of employees
Current staff
Staff numbers
83
Abeona Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 21:16
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/15
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.